Salvador Bofill, F. J., Moreno Antón, F., Rodríguez Sánchez, C. A., Galve Calvo, E., Hernando Melia, C., Gil, C., . . . Martín, M. (2022). Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial.
Citación estilo ChicagoSalvador Bofill, Francisco Javier, Fernando Moreno Antón, César Augusto Rodríguez Sánchez, Elena Galve Calvo, Cristina Hernando Melia, Ciruelos Gil, Luis de la Cruz Merino, y Miguel Martín. Safety and Efficacy of Ribociclib Plus Letrozole in Patients With HR+, HER2– Advanced Breast Cancer: Results From the Spanish Sub-population of the Phase 3b CompLEEment-1 Trial. 2022.
Cita MLASalvador Bofill, Francisco Javier, et al. Safety and Efficacy of Ribociclib Plus Letrozole in Patients With HR+, HER2– Advanced Breast Cancer: Results From the Spanish Sub-population of the Phase 3b CompLEEment-1 Trial. 2022.